Found 5 matching trials
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PHASE2This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSM...
Status
Active Not Recruiting
Location
City of Hope Comprehensive Cancer Center
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
PHASE3The intention of the study is to demonstrate superiority of AZD2265 relativ...
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
PHASE1The purpose of the study is to evaluate the safety, tolerability, pharmacok...
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
PHASE2The treatment regimen will consist of 4 doses of FPI-2265...
Status
Active Not Recruiting
Location
XCancer Omaha/Urology Cancer Center
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PHASE2This study is an open-label, multicenter study designed to investigate the ...
Status
Active Not Recruiting
Location
Macquarie University Hospital